Haisco Pharmaceutical Group Co., Ltd.

Haisco Pharmaceutical Group Co., Ltd. has shown strong stock performance, gaining 7.46% on March 27, 2026, and outperforming the China Shanghai Composite over various timeframes. The company has achieved significant long-term growth, with a 134.64% increase over three years and a 238.07% rise over the past decade.

Haisco Pharmaceutical Group Co., Ltd. saw a significant stock decline on March 23, 2026, amid a challenging trading session. Despite recent fluctuations, the company has shown strong annual returns and impressive long-term growth, although it faces valuation challenges with a high price-to-earnings ratio and modest return on equity.

Haisco Pharmaceutical Group Co., Ltd. saw a significant intraday increase on March 17, 2026, contrasting with a decline in the broader market. The company has shown positive weekly and monthly trends, with impressive annual returns, though it faces challenges with a high price-to-earnings ratio and modest dividend yield.

Haisco Pharmaceutical Group Co., Ltd. has seen significant stock performance, rising 5.46% today and achieving an intraday high of CNY 49.18. Over the past year, the company has gained 41.65%, outperforming the broader market, while maintaining a strong long-term growth trajectory with substantial increases over three and five years.

Haisco Pharmaceutical Group Co., Ltd. has seen notable stock activity, achieving an intraday high and a weekly gain of over 10%. Despite a year-to-date decline, the company boasts a strong one-year performance and a market capitalization of CNY 25,698 million, with a price-to-earnings ratio of 141.00.

Haisco Pharmaceutical Group Co., Ltd. saw a significant stock increase today, contrasting with the modest rise of the China Shanghai Composite. Over the past year, Haisco has achieved a strong annual return, despite a year-to-date decline, and maintains a notable market capitalization within the Pharmaceuticals & Biotechnology sector.

Haisco Pharmaceutical Group Co., Ltd. faced a significant decline in stock performance, with a notable drop today and over the past week. Despite a challenging year-to-date performance, the company has shown substantial growth over three and five years. Key financial metrics reflect a high price-to-earnings ratio and modest dividend yield.

Haisco Pharmaceutical Group Co., Ltd. faced a decline in stock performance, with a notable drop today and a significant decrease over the past week. Year-to-date, the stock has decreased, contrasting with broader market gains. The company has a high price-to-earnings ratio and a modest dividend yield, indicating a complex financial landscape.